{"entity":{"id":"cdh6","kind":"target","name":"CDH6","aka":[],"tldr":"CDH6 is an adhesion protein from kidney development that reappears on ovarian and kidney cancers.","summary":"Cadherin-6 (CDH6) is a type II cadherin and a fetal kidney marker that is overexpressed in ovarian cancer and renal cell carcinoma with low normal adult expression, the profile an ADC target needs. It is found in 65-85% of ovarian cancers, particularly high-grade serous, and 60-80% of renal cell carcinomas by IHC. Raludotatug deruxtecan (R-DXd), a CDH6 ADC with the DXd payload, is in phase 3 in platinum-resistant ovarian cancer (REJOICE-Ovarian01). The main open question is whether the DXd payload's interstitial lung disease signal and the expression threshold for benefit will hold up in a randomised setting. The simple version is an adhesion protein from kidney development that reappears on ovarian and kidney cancers, giving an ADC a clean address.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/CDH6","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/CDH6"}],"tags":["adc-target"],"related":[],"cancers":["ovarian","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["raludotatug-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"CDH6","role":[],"sources":[],"specificity":"tumour-associated","distribution":"few-types","specificityNote":"Tumour-associated overexpression: 1 cell-killing or cell-finding medicine (Raludotatug deruxtecan) aim at the antigen, which HPA finds stained high in 2 normal tissues; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA CDH6: RNA tissue enhanced (blood vessel 12 nTPM, kidney 14 nTPM); high antibody staining in 2 normal tissues; highest cancer staining renal cancer (1 of 11 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Renal cell carcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas CDH6 tissue","url":"https://www.proteinatlas.org/ENSG00000113361-CDH6/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas CDH6 pathology","url":"https://www.proteinatlas.org/ENSG00000113361-CDH6/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000113361 associations","url":"https://platform.opentargets.org/target/ENSG00000113361/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:1765","ensembl":"ENSG00000113361","uniprot":"P55285","entrez":"1004","firstDescribed":1991,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Suzuki et al, Cell Regul, 1991, \"Diversity of the cadherin family: evidence for eight new cadherins in nervous tissue\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2059658/","biology":"CDH6 is a type II cadherin and a fetal kidney marker.","whereFound":["Ovarian","Renal cell carcinoma"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"ovarian","pct":"65-85","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/CDH6","note":"High-grade serous"},{"cancerId":"rcc","pct":"60-80","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/CDH6"}]},"route":"/targets/cdh6/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/"}],"trial":[{"id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","route":"/trials/rejoice-ovarian01/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}]}}